Difference between revisions of "Team:MIT"
| Line 8: | Line 8: | ||
<div class="column full_size" > | <div class="column full_size" > | ||
<h2> Genetic Circuit to Sense Endometriosis </h2> | <h2> Genetic Circuit to Sense Endometriosis </h2> | ||
| − | <p> This year the MIT iGEM team is creating a circuit constructed of five plasmids that will be able to sense the presence of enodmetriosis in affected women. It will function through a double-check, two "latch" system, checking the cells' miRNA profiles in both the estrogen-high proliferative phase and the estrogen-low secretory phase of the menstrual cycle. While the team is still unsure if the circuit will function as a diagnostic tool, a treatment, or some combination of the two, the design of the circuit upstream of the output has been completed. | + | <p> This year the MIT iGEM team is creating a circuit constructed of five plasmids that will be able to sense the presence of enodmetriosis in affected women. It will function through a double-check, two "latch" system, checking the cells' miRNA profiles in both the estrogen-high proliferative phase and the estrogen-low secretory phase of the menstrual cycle. While the team is still unsure if the circuit will function as a diagnostic tool, a treatment, or some combination of the two, the design of the circuit upstream of the output has been completed. <br><br> |
| − | The circuit will first rely on endogenous estrogen receptors (ERa) to report the presence of etrogen to the circuit through an ERa binding region called ERE in a synthetic promoter. | + | The circuit will first rely on endogenous estrogen receptors (ERa) to report the presence of etrogen to the circuit through an ERa binding region called ERE in a synthetic promoter.<br><br> |
| − | In the estrogen high phase-reactive half of the circuit, this interaction, combined with the correct miRNA conditions, will activate the expression of a recombinase that will flip the first latch before the output. The wrong miRNA conditions will result in the degredation of the recombinase genes's mRNA, and the lack of a small molecule drug will result in the degredation of the protein if by chance the recombinase mRNA reaches a ribosome before it is degraded by the miRNA complex. This is because the recombinase will be synthetically combined with a degredation tag, DDd, that is stabilized by that small molecule drug. | + | In the estrogen high phase-reactive half of the circuit, this interaction, combined with the correct miRNA conditions, will activate the expression of a recombinase that will flip the first latch before the output. The wrong miRNA conditions will result in the degredation of the recombinase genes's mRNA, and the lack of a small molecule drug will result in the degredation of the protein if by chance the recombinase mRNA reaches a ribosome before it is degraded by the miRNA complex. This is because the recombinase will be synthetically combined with a degredation tag, DDd, that is stabilized by that small molecule drug.<br><br> |
| − | In the estrogen low phase-reactive half of the circuit, the binding of ERa to the synthetic promoter region activates expression of a repressor protein that prevents the expression of the second recombinase. This way, when there is very little estrogen, the repressor is not expressed in significant amounts and the constitutive promoter before the recombinase can activate its expression. As before, the miRNA profile of the cell in the estrogen low phase is used to degrade mRNA of the repressor at that point, and degrades the mRNA of the recombinase during the estrogen high phase. The second recombinase is also controlled by a degredation tag and small molecule drug. Through this system of repressors, the team hopes that the second recombinase will only be expressed in the estrogen low phase. | + | In the estrogen low phase-reactive half of the circuit, the binding of ERa to the synthetic promoter region activates expression of a repressor protein that prevents the expression of the second recombinase. This way, when there is very little estrogen, the repressor is not expressed in significant amounts and the constitutive promoter before the recombinase can activate its expression. As before, the miRNA profile of the cell in the estrogen low phase is used to degrade mRNA of the repressor at that point, and degrades the mRNA of the recombinase during the estrogen high phase. The second recombinase is also controlled by a degredation tag and small molecule drug. Through this system of repressors, the team hopes that the second recombinase will only be expressed in the estrogen low phase.<br><br> |
The first possible output would be the apoptosis of cells identified by the circuit as endometriotic. This is a risky option as there is a chance for leaky expression of the recombinases despite the number of repressors. The second possible output would be a fluorescence gene, so the disease cells can be more easily identified during surgery, allowing for better complete removal of the lesions. This is a less ideal option because through the circuit, the team hopes to decrease the need for women with endometriosis to undergo surgery, and while this output may decrease the number of surgeries required, it would not provide an alternative to surgery. The third possible output would be the production of a biomarker that can be sensed through blood or urine testing as a diagnostic, an alternative to laparoscopic surgery that is the sole diagnostic tool at this time. This option would remove the need for one surgery, but would not be able to actually provide a treatment. It's also possible to do a combination of these outputs. | The first possible output would be the apoptosis of cells identified by the circuit as endometriotic. This is a risky option as there is a chance for leaky expression of the recombinases despite the number of repressors. The second possible output would be a fluorescence gene, so the disease cells can be more easily identified during surgery, allowing for better complete removal of the lesions. This is a less ideal option because through the circuit, the team hopes to decrease the need for women with endometriosis to undergo surgery, and while this output may decrease the number of surgeries required, it would not provide an alternative to surgery. The third possible output would be the production of a biomarker that can be sensed through blood or urine testing as a diagnostic, an alternative to laparoscopic surgery that is the sole diagnostic tool at this time. This option would remove the need for one surgery, but would not be able to actually provide a treatment. It's also possible to do a combination of these outputs. | ||
Revision as of 16:08, 27 June 2016
Genetic Circuit to Sense Endometriosis
This year the MIT iGEM team is creating a circuit constructed of five plasmids that will be able to sense the presence of enodmetriosis in affected women. It will function through a double-check, two "latch" system, checking the cells' miRNA profiles in both the estrogen-high proliferative phase and the estrogen-low secretory phase of the menstrual cycle. While the team is still unsure if the circuit will function as a diagnostic tool, a treatment, or some combination of the two, the design of the circuit upstream of the output has been completed.
The circuit will first rely on endogenous estrogen receptors (ERa) to report the presence of etrogen to the circuit through an ERa binding region called ERE in a synthetic promoter.
In the estrogen high phase-reactive half of the circuit, this interaction, combined with the correct miRNA conditions, will activate the expression of a recombinase that will flip the first latch before the output. The wrong miRNA conditions will result in the degredation of the recombinase genes's mRNA, and the lack of a small molecule drug will result in the degredation of the protein if by chance the recombinase mRNA reaches a ribosome before it is degraded by the miRNA complex. This is because the recombinase will be synthetically combined with a degredation tag, DDd, that is stabilized by that small molecule drug.
In the estrogen low phase-reactive half of the circuit, the binding of ERa to the synthetic promoter region activates expression of a repressor protein that prevents the expression of the second recombinase. This way, when there is very little estrogen, the repressor is not expressed in significant amounts and the constitutive promoter before the recombinase can activate its expression. As before, the miRNA profile of the cell in the estrogen low phase is used to degrade mRNA of the repressor at that point, and degrades the mRNA of the recombinase during the estrogen high phase. The second recombinase is also controlled by a degredation tag and small molecule drug. Through this system of repressors, the team hopes that the second recombinase will only be expressed in the estrogen low phase.
The first possible output would be the apoptosis of cells identified by the circuit as endometriotic. This is a risky option as there is a chance for leaky expression of the recombinases despite the number of repressors. The second possible output would be a fluorescence gene, so the disease cells can be more easily identified during surgery, allowing for better complete removal of the lesions. This is a less ideal option because through the circuit, the team hopes to decrease the need for women with endometriosis to undergo surgery, and while this output may decrease the number of surgeries required, it would not provide an alternative to surgery. The third possible output would be the production of a biomarker that can be sensed through blood or urine testing as a diagnostic, an alternative to laparoscopic surgery that is the sole diagnostic tool at this time. This option would remove the need for one surgery, but would not be able to actually provide a treatment. It's also possible to do a combination of these outputs.
Before you start:
Please read the following pages:
Styling your wiki
You may style this page as you like or you can simply leave the style as it is. You can easily keep the styling and edit the content of these default wiki pages with your project information and completely fulfill the requirement to document your project.
While you may not win Best Wiki with this styling, your team is still eligible for all other awards. This default wiki meets the requirements, it improves navigability and ease of use for visitors, and you should not feel it is necessary to style beyond what has been provided.
Wiki template information
We have created these wiki template pages to help you get started and to help you think about how your team will be evaluated. You can find a list of all the pages tied to awards here at the Pages for awards link. You must edit these pages to be evaluated for medals and awards, but ultimately the design, layout, style and all other elements of your team wiki is up to you!
Editing your wiki
On this page you can document your project, introduce your team members, document your progress and share your iGEM experience with the rest of the world!
Tips
This wiki will be your team’s first interaction with the rest of the world, so here are a few tips to help you get started:
- State your accomplishments! Tell people what you have achieved from the start.
- Be clear about what you are doing and how you plan to do this.
- You have a global audience! Consider the different backgrounds that your users come from.
- Make sure information is easy to find; nothing should be more than 3 clicks away.
- Avoid using very small fonts and low contrast colors; information should be easy to read.
- Start documenting your project as early as possible; don’t leave anything to the last minute before the Wiki Freeze. For a complete list of deadlines visit the iGEM 2016 calendar
- Have lots of fun!
Inspiration
You can also view other team wikis for inspiration! Here are some examples:
Uploading pictures and files
You can upload your pictures and files to the iGEM 2016 server. Remember to keep all your pictures and files within your team's namespace or at least include your team's name in the file name.
When you upload, set the "Destination Filename" to Team:YourOfficialTeamName/NameOfFile.jpg. (If you don't do this, someone else might upload a different file with the same "Destination Filename", and your file would be erased!)
